Navigation Links
UPCI researchers target 'cell sleep' to lower chances of cancer recurrence
Date:8/1/2013

PITTSBURGH, Aug. 1, 2013 An international research team led by University of Pittsburgh Cancer Institute (UPCI) scientists discovered that by preventing cancer cells from entering a state of cellular sleep, cancer drugs are more effective, and there is a lower chance of cancer recurrence. The findings, which will be published in the August 15 issue of the journal Cancer Research and are available online, are the first to show that it is possible to therapeutically target cancer cells to keep them from entering a cellular state called quiescence, or "cell sleep." Quiescence can be a dangerous source of tumor recurrence because cancer drugs don't typically destroy quiescent cells.

"Successful cancer therapy often is hampered by tumor cell quiescence because these cells remain viable and are a reservoir for tumor progression," said Anette Duensing, M.D., assistant professor of pathology at UPCI. "By inhibiting a key regulator of quiescence, we are able to kill a larger fraction of cancer cells."

Dr. Duensing and her colleagues made the discovery while studying gastrointestinal stromal tumors (GISTs), which are uncommon tumors that begin in the walls of the gastrointestinal tract. According to the American Cancer Society, about 5,000 cases of GISTs occur each year in the United States with an estimated five-year survival rate of 45 percent in patients with advanced disease.

GISTs are caused by a single gene mutation, which means they can be successfully treated with the targeted therapy drug imatinib, known by the trade name Gleevec. Unlike traditional chemotherapy, which kills all rapidly dividing cells, targeted therapy stops cancer by interfering with specific molecules needed for tumor growth.

Unfortunately, GISTs rapidly develop resistance to the treatment and complete cancer remission using Gleevec is rare. A key regulator of the cancer cell sleep process is a protein complex called DREAM, which is named for the multiple proteins involved. Gleevec induces cell sleep using the DREAM complex, which means that the drug intrinsically limits its own effectiveness.

"When we disrupted the DREAM complex in the lab, we significantly increased cancer cell death using Gleevec," said Dr. Duensing. "This underscores the importance of the DREAM complex as a novel drug target worthy of preclinical and clinical investigations."


'/>"/>

Contact: Allison Hydzik
hydzikam@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
3. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
4. UNH researchers find African farmers need better climate change data to improve farming practices
5. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
6. Researchers uncover molecular pathway through which common yeast becomes fungal pathogen
7. Researchers print live cells with a standard inkjet printer
8. Columbia Engineering and Penn researchers increase speed of single-molecule measurements
9. Researchers reveal how a single gene mutation leads to uncontrolled obesity
10. Researchers discover novel therapy for Crohns disease
11. New paper by Notre Dame researchers describes method for cleaning up nuclear waste
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/7/2017)... March 7, 2017 Brandwatch , the leading social ... The Prince,s Trust to uncover insights to support its reporting, ... The UK,s leading youth charity will be using Brandwatch ... and get a better understanding of the topics and issues that ... ...
(Date:3/2/2017)... LONDON , March 2, 2017 Summary ... require to better understand Merck KGaA and its partnering ... report: https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals ... into the partnering activity of one of the world,s ... reports are prepared upon purchase to ensure inclusion of ...
(Date:2/28/2017)...   Acuant , a leading provider of data ... to new and core technologies building upon the acquisition ... and desktop Acuant FRM TM facial recognition and ... time manual review of identity documents by accredited professionals. ... and most accurate capture software to streamline workflows by ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... ... March 27, 2017 , ... IsoPlexis ... against cancer, autoimmune disease and more through a single-cell precision engineering platform, today ... analysis platform developed in the laboratory of Dr. James Heath at the ...
(Date:3/27/2017)... 2017  Perthera,s Chief Bioinformatics Officer and research faculty ... , Ph.D., will be speaking at the American Medical ... March 27, 2017, she will be speaking on the ... Research and Care" (from 10:30 a.m. – 12:00 p.m. ... be a participant in the "Making Precision Oncology Data ...
(Date:3/27/2017)... , March 27, 2017 DarioHealth Corp. ... mobile health and big data solutions, today announced that ... insurance coverage option for U.S. consumers who want to ... DarioHealth has signed strategic alliance agreements with partners ... insurance coverage benefits, and if approved, will supply and ...
(Date:3/24/2017)... March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or the ... China , today announced that its board of directors ... of the plan from March 27, 2017 to March 27, 2018. The ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
Breaking Biology Technology: